+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Oral Proteins & Peptides Market by Product Type (Insulin-Based Proteins, Peptide Therapeutics), Formulation (Capsule Formulations, Liquid Formulations, Powder Formulations), Development Stage, Application, End-User - Global Forecast 2025-2030- Product Image
Oral Proteins & Peptides Market by Product Type (Insulin-Based Proteins, Peptide Therapeutics), Formulation (Capsule Formulations, Liquid Formulations, Powder Formulations), Development Stage, Application, End-User - Global Forecast 2025-2030- Product Image
Sale

Oral Proteins & Peptides Market by Product Type (Insulin-Based Proteins, Peptide Therapeutics), Formulation (Capsule Formulations, Liquid Formulations, Powder Formulations), Development Stage, Application, End-User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 190 Pages
  • March 2025
  • Region: Global
  • 360iResearch™
  • ID: 4968731
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Oral Proteins & Peptides Market grew from USD 6.10 billion in 2023 to USD 6.89 billion in 2024. It is expected to continue growing at a CAGR of 13.27%, reaching USD 14.60 billion by 2030.

The oral proteins and peptides market is experiencing a pivotal moment as advancements in pharmaceutical science converge with evolving healthcare demands. This sector, once considered niche, is now at the forefront of therapeutics innovation, driven by breakthroughs in molecular synthesis, formulation technologies, and targeted delivery systems. Recent developments have redefined patient care and treatment regimens by enhancing bioavailability, minimizing side effects, and offering new solutions for chronic conditions. With chronic diseases continuing to surge globally and an increasing demand for patient-friendly therapeutic options, the market is evolving rapidly. Researchers and industry stakeholders are investing significant resources into exploring novel protein structures and peptide analogues that show promise in managing complex conditions. Alongside clinical achievements, regulatory authorities have played a crucial role by streamlining approval processes, thereby fostering a more attractive environment for advancements in oral drug delivery. This introductory overview sets the stage for a detailed exploration of transformative market dynamics, segmentation specifics, regional trends, competitive landscapes, and strategic action plans designed to guide industry leaders through a complex yet opportunity-rich landscape. The following sections delve deeper into these elements, providing a comprehensive narrative for stakeholders seeking to understand and capitalize on this evolving market.

Transformative Shifts in the Oral Proteins & Peptides Market Landscape

Recent years have witnessed transformative shifts that have irreversibly altered the oral proteins and peptides market. Technological innovations are no longer limited to advanced manufacturing methods but now include state-of-the-art drug delivery systems that promise better patient compliance and improved therapeutic outcomes. This evolution is fueled by an increased understanding of molecular interactions and the biochemistry underlying various disease states. The industry is transitioning from traditional approaches to more dynamic models that incorporate precision medicine and personalized care. Such shifts have been echoed in the accelerated pace of clinical trials and expedited regulatory approvals, reflecting the urgency to meet clinical demands. Furthermore, the recent trend towards interdisciplinary collaborations - merging expertise from biochemistry, nanotechnology, and material sciences - has led to the development of formulations that are both efficacious and patient-centric. These advancements are not only replacing outdated therapeutic models but are also setting the stage for a new era where treatment strategies are optimized for maximum safety and efficiency. The ensuing narrative unpacks critical segmentation and regional insights that complement this transformative journey while offering a strategic roadmap for stakeholders.

Detailed Segmentation Insights Driving Market Evolution

The market’s segmentation plays a central role in understanding the inherent complexities and opportunities within the oral proteins and peptides domain. When assessed based on product type, the industry scrutinizes both insulin-based proteins and peptide therapeutics. Within the insulin-based category, detailed analysis focuses on combination insulin products, long-acting insulin analogues, rapid-acting insulin analogues, and recombinant human insulin. Simultaneously, peptide therapeutics are being examined through the lenses of calcitonin-based therapies, glucagon-like peptide-1 receptor agonists, and vasopressin analogs. Insights drawn from the segmentation based on formulation reveal a diverse landscape that includes capsule formulations, liquid formulations, powder formulations, and tablet formulations, each bringing unique advantages to patient care and compliance. Additionally, evaluating the development stage spans from early-phase clinical trials in Phase I and II, through the rigorous evaluation in Phase III, and extends to post-market surveillance and preclinical studies. Market applications are equally varied, addressing challenges in cancer treatment, cardiovascular diseases, diabetes management, and hormonal disorders. This depth of segmentation further extends to the end-user environment by recognizing applications in home care settings, hospitals and clinics, research laboratories, and specialty clinics. Together, these segmented insights provide a granular understanding that enables industry players to tailor strategies in response to diverse market needs.

Based on Product Type, market is studied across Insulin-Based Proteins and Peptide Therapeutics. The Insulin-Based Proteins is further studied across Combination Insulin Products, Long-Acting Insulin Analogues, Rapid-Acting Insulin Analogues, and Recombinant Human Insulin. The Peptide Therapeutics is further studied across Calcitonin-Based Therapies, Glucagon-Like Peptide-1 Receptor Agonists, and Vasopressin Analogs.

Based on Formulation, market is studied across Capsule Formulations, Liquid Formulations, Powder Formulations, and Tablet Formulations.

Based on Development Stage, market is studied across Phase I & II Clinical Trials, Phase III Clinical Trials, Post-Market Surveillance, and Preclinical Studies.

Based on Application, market is studied across Cancer Treatment, Cardiovascular Diseases, Diabetes Management, and Hormonal Disorders.

Based on End-User, market is studied across Home Care Settings, Hospitals & Clinics, Research Laboratories, and Specialty Clinics.

Regional Perspectives: Insights Across Key Global Markets

Globally, the dynamics of the oral proteins and peptides market are shaped by distinct regional insights that influence both demand and innovation. In the Americas, robust healthcare infrastructure and strong investment in research and development have propelled market growth, fostering a competitive environment where clinical breakthroughs are rapidly implemented. Moving to Europe, the Middle East, and Africa, the market benefits from a combination of established regulatory frameworks and emerging healthcare initiatives. These regions are witnessing a steady rise in patient awareness coupled with governmental efforts to enhance healthcare accessibility, thereby expanding the reach of advanced oral formulations. In the Asia-Pacific, rapid urbanization, enhanced public health spending, and an increasing prevalence of chronic diseases are catalytic forces behind significant market expansion. Each region brings its own challenges and opportunities; for instance, while the Americas offer advanced technological ecosystems, the Asia-Pacific region presents potential for vast growth due to demographic dynamics and rising middle-class populations. Such regional nuances underscore the importance of tailored strategies that address specific regulatory landscapes, economic conditions, and consumer behaviors, thereby enabling stakeholders to optimize market entry and growth strategies across these diverse geographies.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Insightful Overview of Leading Companies Shaping the Industry

The competitive landscape within the oral proteins and peptides market is characterized by a global roster of innovative companies that are strategically positioned across various segments. Industry leaders such as AbbVie Inc., Amgen Inc., and Amryt Pharma plc are at the forefront of redefining therapeutic modalities with a focus on both efficacy and patient safety. Notable contributions from Astellas Pharma Inc., AstraZeneca PLC, and Biocon Limited have further strengthened the market through continuous investments in research, development, and pioneering drug formulations. Other key players, including Boehringer Ingelheim International GmbH, Catalent, Inc., and Entera Bio Ltd. by DNA Biomedical Solutions, have shown remarkable agility in adapting to dynamic regulatory landscapes while expanding their product portfolios. F. Hoffmann-La Roche AG, Hunan Huateng Pharmaceutical Co., Ltd. by Tasly Capital, along with Johnson & Johnson Services, Inc., and Merck KGaA, have been influential in leveraging novel biotechnological innovations. This momentum is further augmented by Novartis AG, Novo Nordisk A/S, Oramed Pharmaceuticals Inc., and PeptiDream Inc., who continue to push the boundaries of therapeutic science. Contributions from Pfizer, Inc., Protagonist Therapeutics, Inc., Proxima Concepts Limited, and Rani Therapeutics, LLC are complemented by strategic ventures from Sanofi S.A., Tarsa Therapeutics, Inc., Teva Pharmaceutical Industries Ltd., and Zealand Pharma A/S, collectively driving the market towards a future defined by innovation, collaboration, and patient-centric solutions.

The report delves into recent significant developments in the Oral Proteins & Peptides Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Amryt Pharma plc, Astellas Pharma Inc., AstraZeneca PLC, Biocon Limited, Boehringer Ingelheim International GmbH, Catalent, Inc., Entera Bio Ltd. by DNA Biomedical Solutions, F. Hoffmann-La Roche AG, Hunan Huateng Pharmaceutical Co., Ltd. by Tasly Capital, Johnson & Johnson Services, Inc., Merck KGaA, Novartis AG, Novo Nordisk A/S, Oramed Pharmaceuticals Inc., PeptiDream Inc., Pfizer, Inc., Protagonist Therapeutics, Inc., Proxima Concepts Limited, Rani Therapeutics, LLC, Sanofi S.A., Tarsa Therapeutics, Inc., Teva Pharmaceutical Industries Ltd., and Zealand Pharma A/S.

Strategic Recommendations for Market Leaders

Industry leaders must adapt strategically to maintain competitiveness in a market as dynamic as oral proteins and peptides. Forward-thinking executives should prioritize investment in advanced research and development, focusing on the integration of novel formulation techniques and emerging drug delivery systems that enhance patient compliance. Embracing cross-functional collaborations can catalyze innovation while alleviating the risks associated with high-cost research investments. A key recommendation is to leverage real-world data and post-market surveillance insights to continuously refine product pipelines and identify potential market gaps. Additionally, companies should streamline regulatory strategies by developing proactive relationships with global health authorities, thereby ensuring rapid market entry and sustained product success. Diversification across multiple segments - spanning product types, formulations, development stages, and applications - ensures that businesses can mitigate risks and capitalize on varied revenue streams. Leaders are also advised to invest in digital transformation initiatives to enhance operational efficiency and support data-driven decision-making. With growing emphasis on personalized medicine, there is significant merit in tailoring therapeutic solutions to patient-specific needs. By aligning strategic investments with emerging global trends and technological innovations, industry players can secure a competitive edge and drive long-term market growth.

Crafting a Future of Innovation and Growth

In summary, the evolving landscape of oral proteins and peptides presents unprecedented opportunities for healthcare innovation and market growth. This executive summary has highlighted the importance of understanding key market shifts, detailed segmentation insights, and diverse regional dynamics that collectively drive this industry forward. The competitive environment, dominated by distinguished companies, underscores the crucial role of continuous research and strategic collaborations in sustaining innovation. By recognizing the multifaceted nature of product development - from insulin-based proteins and peptide therapeutics to various formulation types, developmental stages, and clinical applications - stakeholders can navigate the complexities inherent in this market with greater precision. The insights provided serve not only as a comprehensive overview of current trends but also as a strategic guide for decision-makers looking to harness the full potential of this sector. Ultimately, the future of oral proteins and peptides is anchored in collaboration, technological advancement, and a steadfast commitment to improving patient outcomes, paving the way for a resilient and dynamic industry.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of chronic diseases demanding innovative oral protein therapeutics
5.1.1.2. Growing need for oral protein and peptide supplements with growing nutritional awareness
5.1.2. Restraints
5.1.2.1. Concerns associated with significant side effects
5.1.3. Opportunities
5.1.3.1. Collaborative partnerships between pharma and biotech companies for advancing oral protein therapies
5.1.3.2. Emerging focus on the development of macrocyclic peptides
5.1.4. Challenges
5.1.4.1. Regulatory hurdles affecting the approval processes for new oral protein-based therapeutics globally
5.2. Market Segmentation Analysis
5.2.1. Product Type: Increasing need for peptide therapeutics targeting bone metabolism disorders and Type 2 diabetes
5.2.2. Formulation: Growing preferences for capsule formulations owing to their ease of administration and ability to protect sensitive biological compounds
5.2.3. Development Stage: Exploring diversities across developmental stages in oral proteins & peptides
5.2.4. Application: Growing demand for oral proteins and peptides in cancer treatment for enhancing patient compliance
5.2.5. End-User: Rising consumer preference for oral proteins and peptides in home care settings
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Oral Proteins & Peptides Market, by Product Type
6.1. Introduction
6.2. Insulin-Based Proteins
6.2.1. Combination Insulin Products
6.2.2. Long-Acting Insulin Analogues
6.2.3. Rapid-Acting Insulin Analogues
6.2.4. Recombinant Human Insulin
6.3. Peptide Therapeutics
6.3.1. Calcitonin-Based Therapies
6.3.2. Glucagon-Like Peptide-1 Receptor Agonists
6.3.3. Vasopressin Analogs
7. Oral Proteins & Peptides Market, by Formulation
7.1. Introduction
7.2. Capsule Formulations
7.3. Liquid Formulations
7.4. Powder Formulations
7.5. Tablet Formulations
8. Oral Proteins & Peptides Market, by Development Stage
8.1. Introduction
8.2. Phase I & II Clinical Trials
8.3. Phase III Clinical Trials
8.4. Post-Market Surveillance
8.5. Preclinical Studies
9. Oral Proteins & Peptides Market, by Application
9.1. Introduction
9.2. Cancer Treatment
9.3. Cardiovascular Diseases
9.4. Diabetes Management
9.5. Hormonal Disorders
10. Oral Proteins & Peptides Market, by End-User
10.1. Introduction
10.2. Home Care Settings
10.3. Hospitals & Clinics
10.4. Research Laboratories
10.5. Specialty Clinics
11. Americas Oral Proteins & Peptides Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Oral Proteins & Peptides Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Oral Proteins & Peptides Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
14.3.1. CordenPharma's EUR 900 million investment aims to transform peptide manufacturing across the US and Europe
14.3.2. Glanbia Nutritionals revolutionizes collagen supplementation with the launch of fast-absorbing Collameta
14.3.3. Incyte expands inflammation portfolio with Escient acquisition, introducing novel oral MRGPR antagonists
14.3.4. Johnson & Johnson achieves promising phase II results with JNJ-2113, a groundbreaking oral peptide for plaque psoriasis
14.3.5. Orbis Medicines revolutionizes oral peptide drug delivery with EUR 26 million funding to enhance patient experience
14.3.6. Novartis acquisition of MorphoSys AG strengthens oncology pipeline with focus on oral proteins and peptides
14.3.7. Innovative partnership between Vivtex and AI Proteins aims to revolutionize oral therapies for inflammation
14.4. Strategy Analysis & Recommendation
14.4.1. AstraZeneca PLC
14.4.2. Johnson & Johnson Services, Inc.
14.4.3. Novo Nordisk A/S
14.4.4. Novartis AG
List of Figures
FIGURE 1. ORAL PROTEINS & PEPTIDES MARKET MULTI-CURRENCY
FIGURE 2. ORAL PROTEINS & PEPTIDES MARKET MULTI-LANGUAGE
FIGURE 3. ORAL PROTEINS & PEPTIDES MARKET RESEARCH PROCESS
FIGURE 4. ORAL PROTEINS & PEPTIDES MARKET SIZE, 2023 VS 2030
FIGURE 5. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 6. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
FIGURE 9. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2023 VS 2030 (%)
FIGURE 11. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2023 VS 2030 (%)
FIGURE 13. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 15. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 17. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 21. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 22. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 23. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 26. ORAL PROTEINS & PEPTIDES MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 27. ORAL PROTEINS & PEPTIDES MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. ORAL PROTEINS & PEPTIDES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ORAL PROTEINS & PEPTIDES MARKET DYNAMICS
TABLE 7. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COMBINATION INSULIN PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY LONG-ACTING INSULIN ANALOGUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RAPID-ACTING INSULIN ANALOGUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RECOMBINANT HUMAN INSULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CALCITONIN-BASED THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY VASOPRESSIN ANALOGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CAPSULE FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY LIQUID FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY POWDER FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY TABLET FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PHASE I & II CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PHASE III CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY POST-MARKET SURVEILLANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRECLINICAL STUDIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CANCER TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HORMONAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 47. ARGENTINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 48. ARGENTINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
TABLE 49. ARGENTINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 50. ARGENTINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 51. ARGENTINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 52. ARGENTINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 54. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 55. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
TABLE 56. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 57. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 61. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 62. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
TABLE 63. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 64. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 65. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 66. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 67. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 68. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 69. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
TABLE 70. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 71. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 72. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 73. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 74. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 83. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 84. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
TABLE 85. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 86. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 87. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 88. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 89. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 90. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 91. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 92. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
TABLE 93. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 94. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 95. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 96. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 97. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 98. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 99. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
TABLE 100. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 101. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 102. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 103. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 104. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 105. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 106. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
TABLE 107. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 108. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 109. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 110. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 111. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 112. INDONESIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 113. INDONESIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
TABLE 114. INDONESIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 115. INDONESIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 116. INDONESIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 117. INDONESIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 118. INDONESIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 119. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 120. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
TABLE 121. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 122. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 123. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 124. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 125. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 126. MALAYSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 127. MALAYSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
TABLE 128. MALAYSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 129. MALAYSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 130. MALAYSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 131. MALAYSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 132. MALAYSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 133. PHILIPPINES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 134. PHILIPPINES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
TABLE 135. PHILIPPINES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 136. PHILIPPINES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 137. PHILIPPINES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 138. PHILIPPINES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 139. PHILIPPINES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 140. SINGAPORE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 141. SINGAPORE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
TABLE 142. SINGAPORE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 143. SINGAPORE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 144. SINGAPORE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 145. SINGAPORE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 146. SINGAPORE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 147. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 148. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
TABLE 149. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 150. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 151. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 152. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 153. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 154. TAIWAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 155. TAIWAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
TABLE 156. TAIWAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 157. TAIWAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 158. TAIWAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 159. TAIWAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 160. TAIWAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 161. THAILAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 162. THAILAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
TABLE 163. THAILAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 164. THAILAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 165. THAILAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 166. THAILAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 167. THAILAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 168. VIETNAM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 169. VIETNAM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
TABLE 170. VIETNAM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 171. VIETNAM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 172. VIETNAM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 173. VIETNAM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 174. VIETNAM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 183. DENMARK ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 184. DENMARK ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
TABLE 185. DENMARK ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 186. DENMARK ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 187. DENMARK ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 188. DENMARK ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 189. DENMARK ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 190. EGYPT ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 191. EGYPT ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
TABLE 192. EGYPT ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 193. EGYPT ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 194. EGYPT ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 195. EGYPT ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 196. EGYPT ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 197. FINLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 198. FINLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
TABLE 199. FINLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 200. FINLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 201. FINLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 202. FINLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 203. FINLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 204. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 205. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
TABLE 206. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 207. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 208. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 209. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 210. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 211. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 212. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
TABLE 213. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 214. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 215. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 216. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 217. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 218. ISRAEL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 219. ISRAEL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
TABLE 220. ISRAEL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 221. ISRAEL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 222. ISRAEL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 223. ISRAEL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 224. ISRAEL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 225. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 226. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
TABLE 227. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 228. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 229. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 230. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 231. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 232. NETHERLANDS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 233. NETHERLANDS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
TABLE 234. NETHERLANDS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 235. NETHERLANDS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 236. NETHERLANDS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 237. NETHERLANDS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 238. NETHERLANDS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 239. NIGERIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 240. NIGERIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
TABLE 241. NIGERIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 242. NIGERIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 243. NIGERIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 244. NIGERIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 245. NIGERIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 246. NORWAY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 247. NORWAY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
TABLE 248. NORWAY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 249. NORWAY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 250. NORWAY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 251. NORWAY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 252. NORWAY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 253. POLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 254. POLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
TABLE 255. POLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 256. POLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 257. POLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 258. POLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 259. POLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 260. QATAR ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 261. QATAR ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
TABLE 262. QATAR ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 263. QATAR ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 264. QATAR ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 265. QATAR ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 266. QATAR ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 267. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 268. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
TABLE 269. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 270. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 271. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 272. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 273. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 274. SAUDI ARABIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 275. SAUDI ARABIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
TABLE 276. SAUDI ARABIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 277. SAUDI ARABIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 278. SAUDI ARABIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 279. SAUDI ARABIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 280. SAUDI ARABIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 281. SOUTH AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 282. SOUTH AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
TABLE 283. SOUTH AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 284. SOUTH AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 285. SOUTH AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 286. SOUTH AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 287. SOUTH AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 288. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 289. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
TABLE 290. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 291. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 292. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 293. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 294. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 295. SWEDEN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 296. SWEDEN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
TABLE 297. SWEDEN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 298. SWEDEN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 299. SWEDEN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 300. SWEDEN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 301. SWEDEN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 302. SWITZERLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 303. SWITZERLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
TABLE 304. SWITZERLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 305. SWITZERLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 306. SWITZERLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 307. SWITZERLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 308. SWITZERLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 309. TURKEY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 310. TURKEY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
TABLE 311. TURKEY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 312. TURKEY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 313. TURKEY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 314. TURKEY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 315. TURKEY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 316. UNITED ARAB EMIRATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 317. UNITED ARAB EMIRATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
TABLE 318. UNITED ARAB EMIRATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 319. UNITED ARAB EMIRATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 320. UNITED ARAB EMIRATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 321. UNITED ARAB EMIRATES ORAL PROTEINS & PEPTIDES MARKET SIZE,

Companies Mentioned

  • AbbVie Inc.
  • Amgen Inc.
  • Amryt Pharma plc
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Biocon Limited
  • Boehringer Ingelheim International GmbH
  • Catalent, Inc.
  • Entera Bio Ltd. by DNA Biomedical Solutions
  • F. Hoffmann-La Roche AG
  • Hunan Huateng Pharmaceutical Co., Ltd. by Tasly Capital
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • PeptiDream Inc.
  • Pfizer, Inc.
  • Protagonist Therapeutics, Inc.
  • Proxima Concepts Limited
  • Rani Therapeutics, LLC
  • Sanofi S.A.
  • Tarsa Therapeutics, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Zealand Pharma A/S

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages190
PublishedMarch 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 6.89 Billion
Forecasted Market Value ( USD ) by 2030 $ 14.6 Billion
Compound Annual Growth Rate13.2%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Oral Proteins & Peptides Market by Molecule (Semaglutide, Linaclotide, Calcitonin), Drug Class (GLP-1 Receptor Agonist, GEP, CGRP), Therapeutic Area (Diabetes, Gastroenterology, Genetic Disorder), Formulation (Tablet, Capsule) - Global Forecast to 2029 - Product Image

Oral Proteins & Peptides Market by Molecule (Semaglutide, Linaclotide, Calcitonin), Drug Class (GLP-1 Receptor Agonist, GEP, CGRP), Therapeutic Area (Diabetes, Gastroenterology, Genetic Disorder), Formulation (Tablet, Capsule) - Global Forecast to 2029

  • Report
  • 323 Pages
  • Global
From
Oral Proteins & Peptides Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Oral Proteins & Peptides Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Oral Proteins and Peptides Market Size, Share, Trends, and Forecast 2025-2033 - Product Image

Oral Proteins and Peptides Market Size, Share, Trends, and Forecast 2025-2033

  • Report
  • 138 Pages
  • Global
From
Oral Proteins and Peptides Market Report 2025 - Product Image

Oral Proteins and Peptides Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Oral Solid Dosage Pharmaceutical Formulation Market Report 2025 - Product Image

Oral Solid Dosage Pharmaceutical Formulation Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.